Study Identifies New Links Between Monocytes, T1D Progression
A new report builds on previous research that could help scientists better understand type 1 diabetes (T1D) risk.
Source: ajmc.com
Recent Onset Type News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Recent Onset Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Recent Onset Type Today - Breaking & Trending Today
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
MINNEAPOLIS, April 06, 2023 -- Panbela Therapeutics, Inc. , a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today... | April 6, 2023
Source: marketscreener.com
Are we proof that a new drug to stop diseases like arthritis and type 1 diabetes really DOES work?
Mahn Singh is the first British child to be part of a trial for a new drug, teplizumab, which blocks the immune system malfunction that destroys insulin-producing cells and causes type 1 diabetes.
Source: dailymail.co.uk
Provention Bio Reports Third Quarter 2021 Financial Results and Provides Business Update
/PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today...
Source: prnewswire.com
Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update
Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update News provided by Share this article Share this article RED BANK, N.J., May 6, 2021 /PRNewswire/ --Â Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results and provided a business update for the first quarter ended March 31, 2021. "The first quarter of 2021 marked another quarter of strong execution across Provention Bio as we continue to advance our portfolio of autoimmunology therapeutic candidate...
Source: prnewswire.com